The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 23, 2023
Filed:
Oct. 26, 2022
Applicants:
Ecofibre Limited, Georgetown, AU;
The University of Newcastle, Callaghan, AU;
Inventors:
Alexandra M. Capano, Philadelphia, PA (US);
Pradeep Singh Tanwar, Fletcher, AU;
Alex Nance, Georgetown, KY (US);
Assignees:
Ecofibre Limited, Georgetown, KY (US);
The University of Newcastle, NSW, AU;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 36/00 (2006.01); A61K 36/185 (2006.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 31/7068 (2006.01); A61K 31/675 (2006.01); A61K 31/7048 (2006.01); A61K 31/4745 (2006.01); A61K 31/704 (2006.01); A61K 31/198 (2006.01); A61K 31/519 (2006.01); A61K 31/395 (2006.01); A61K 31/282 (2006.01); A61K 33/243 (2019.01); A61K 31/352 (2006.01); A61K 31/01 (2006.01); A61K 31/015 (2006.01); A61K 31/355 (2006.01); A61K 31/513 (2006.01); A61K 39/395 (2006.01); A61K 31/05 (2006.01);
U.S. Cl.
CPC ...
A61K 36/185 (2013.01); A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/05 (2013.01); A61K 31/198 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/352 (2013.01); A61K 31/355 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/5545 (2017.08); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01);
Abstract
Methods for treating ovarian cancer comprising: administering to a patient and effective amount of a cannabis extract comprising CBD, wherein preferably, the cannabis extract is administered via a mucosal formulation.